8 recruiting, 1 active not recruiting, 1 terminated, 1 unknown. 11 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Recruiting 8, Active not recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 7 | Recruiting 4, Active not recruiting 1, Terminated 1, Unknown 1 |
Follow Relapsed Cancer: new trials by email Literature Review of Relapsed Cancer trials Research Report on Relapsed Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma LMP744, Conventional Surgery or Biopsy - Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Phase 1 / Phase 2 | Recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 40 | 2026-07-15 | 2026-10-16 |
| Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) Roginolisib, Venetoclax, Rituximab - Leukemia, Relapsed Leukemia | Phase 1 / Phase 2 | Recruiting | Jennifer R. Brown, MD, PhD | 64 | 2025-03-19 | 2026-02-11 |
| A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies Tacabrutideg, Sonrotoclax, Zanubrutinib - B-cell Malignancy, Relapsed Cancer | Phase 1 / Phase 2 | Recruiting | BeOne Medicines | 80 | 2024-11-27 | 2026-09-11 |
| Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma Isatuximab, Belantamab mafodotin, Pomalidomide - Relapsed Cancer, Refractory Multiple Myeloma | Phase 2 | Recruiting | Massachusetts General Hospital | 50 | 2024-05-31 | 2026-01-14 |
| Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas Pemetrexed, Zanubrutinib, Autologous Stem Cell Transplant (ASCT) - Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma | Phase 2 | Recruiting | Baptist Health South Florida | 15 | 2024-04-25 | 2026-03-03 |
| Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma AutoSCT OR CAR T-cell Therapy, GDP, Epcoritamab - Large Cell Lymphoma, Diffuse, Relapsed Cancer | Phase 2 | Recruiting | Vijendra Singh | 35 | 2023-10-31 | 2026-11-05 |
| A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody HST-1011, Cemiplimab - Solid Tumor, Adult, Relapsed Cancer | Phase 1 / Phase 2 | Active not recruiting | HotSpot Therapeutics, Inc | 77 | 2023-03-15 | 2025-02-04 |
| Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma Pembrolizumab, Bendamustine Hydrochloride - Classical Hodgkin Lymphoma, Relapsed Cancer | Phase 2 | Recruiting | University Health Network, Toronto | 40 | 2021-12-20 | 2026-06-23 |
| Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers Enasidenib, Venetoclax - Acute Myeloid Leukemia, Relapsed Cancer | Phase 1 / Phase 2 | Terminated | University Health Network, Toronto | 27 | 2020-11-05 | 2024-01-24 |
| Pembrolizumab, Ibrutinib and Rituximab in PCNSL Ibrutinib, Pembrolizumab, Rituximab - Primary Central Nervous System Lymphoma, Recurrent Cancer | Phase 1 / Phase 2 | Recruiting | Dana-Farber Cancer Institute | 37 | 2020-08-01 | 2026-10-21 |
| Lorlatinib Combinations in Lung Cancer Lorlatinib, Crizotinib, Binimetinib - Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation | Phase 1 / Phase 2 | Unknown | Massachusetts General Hospital | 96 | 2020-05-01 | 2021-03-10 |
Recurrence (11) · Neoplasms (8) · Brain Neoplasms (1) · Central Nervous System Neoplasms (1) · Glioblastoma (1) · Glioma (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lung Neoplasms (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Multiple Myeloma (1) · Neoplasms by Histologic Type (1) · Neoplasms, Nerve Tissue (1)
Disease Attributes (11) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Hemic and Lymphatic Diseases (5) · Neoplasms by Histologic Type (5) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphoproliferative Disorders (4) · Hematologic Diseases (3) · Lymphatic Diseases (3) · Neoplasms (3) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Neoplasms by Site (2) · Astrocytoma (1)
Rituximab (2) · pembrolizumab (2) · venetoclax (2) · zanubrutinib (2) · Automobiles (1) · Bendamustine Hydrochloride (1) · Biopsy (1) · Crizotinib (1) · Dexamethasone (1) · Guanosine Diphosphate (1) · Immunotherapy, Adoptive (1) · Pemetrexed (1) · Receptors, Chimeric Antigen (1) · Transplantation, Autologous (1) · belantamab mafodotin (1)
Massachusetts General Hospital (2) · University Health Network, Toronto (2) · Baptist Health South Florida (1) · BeOne Medicines (1) · Dana-Farber Cancer Institute (1) · HotSpot Therapeutics, Inc (1) · Jennifer R. Brown, MD, PhD (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Vijendra Singh (1)
United States (9) · Canada (3) · Australia (1) · Brazil (1) · China (1) · Germany (1) · Italy (1) · New Zealand (1) · Poland (1) · Spain (1)
Alison O'Neill, MD (1) · Andrew Yee, MD (1) · Ibiayi Dagogo-Jack, MD (1) · Jennifer Brown, MD, PhD (1) · John Kuruvilla, M.D. (1) · Lakshmi Nayak, MD (1) · Sadhana Jackson, M.D. (1) · Steven Chan, M.D. (1) · Vijendra Singh, MD (1) · Yuliya Linhares, M.D. (1)